ST. LOUIS, Dec. 14, 2016 /PRNewswire/ -- Express
Scripts Holding Company (Nasdaq: ESRX) anticipates achieving
adjusted earnings per diluted share1 for 2017 in the
range of $6.82 to $7.02, representing
growth of 7% to 10% from the midpoint of our 2016 adjusted EPS
guidance range.
"Our value proposition is clear; our opportunities to help
patients and payers contain healthcare costs and improve clinical
outcomes have never been greater," said Tim
Wentworth, CEO and President. "As we continue to evolve
our technological capabilities, expand the reach of our pharmacies,
and enhance our patient experience, we believe we are well
positioned to grow as a unique market force creating value and
driving out waste in healthcare."
To better reflect utilization patterns that have developed over
time as we align our products and offerings to deliver greater
value through both the retail and home delivery channels, the
Company is revising its methodology for reporting network claims
for its 2017 financial guidance and for reporting periods beginning
with the year ending December 31,
2016. Specifically, the revised methodology includes an
adjustment to reflect non-specialty network claims filled through
our 90-day network programs. These claims are now multiplied by
three, as these claims, on average, typically cover a time period
three times longer than other network claims. Home delivery
claims will continue to be multiplied by three, consistent with
prior practice. Solely as the direct result of the revised
methodology, the Company is updating its previously issued 2016
total adjusted claims guidance from a range of 1,265 million to
1,280 million to a range of 1,400 million to 1,415 million.
|
Estimated Guidance
Ranges
|
(in millions,
except per share data)
|
Year Ending
December 31,
2017
|
Adjusted earnings per
diluted share1
|
$6.82 to
$7.02
|
Total adjusted
claims
|
1,375 to
1,4252
|
EBITDA1,3
|
$7,310 to
$7,510
|
Diluted weighted
average shares outstanding during the period
|
580 to 600
|
Cash flow from
operations
|
$4,700 to
$5,200
|
|
|
1
|
See "Supplemental
Information Regarding Non-GAAP Financial Measures" below for a
discussion of the non-GAAP financial measures included in this
press release.
|
2
|
Range reflects the
Company's new claims reporting methodology described
above.
|
3
|
"EBITDA" is earnings
before income taxes, depreciation and amortization and other
expense and is presented throughout this press release as
attributable to Express Scripts, excluding non-controlling interest
representing the share allocated to members of our consolidated
affiliates.
|
The Company updates its previously issued 2016 EPS guidance from
a range of $4.47 to $4.53 to a range
of $5.28 to $5.34, driven by the
previously disclosed impact from discrete tax benefits per diluted
share of $0.81 related to the
disposition of PolyMedica Corporation (Liberty). The Company
reaffirms its previously issued 2016 full year adjusted EPS
guidance range of $6.36 to $6.42 and
EBITDA guidance range of $7,230 million to
$7,330 million.
About Express Scripts
Express Scripts puts medicine within reach of tens of millions
of people by aligning with plan sponsors, taking bold action and
delivering patient-centered care to make better health more
affordable and accessible.
Headquartered in St. Louis,
Express Scripts provides integrated pharmacy benefit management
services, including network-pharmacy claims processing, home
delivery pharmacy care, specialty pharmacy care, specialty benefit
management, benefit-design consultation, drug utilization review,
formulary management, and medical and drug data analysis services.
Express Scripts also distributes a full range of biopharmaceutical
products and provides extensive cost-management and patient-care
services.
For more information, visit Lab.Express-Scripts.com or follow
@ExpressScripts on Twitter.
Supplemental Information Regarding Non-GAAP Financial
Measures
The following provides supplemental information regarding the
non-GAAP financial measures presented herein, including the
reconciliation of such measures to the most directly comparable
financial measures calculated in accordance with U.S. generally
accepted accounting principles ("GAAP"). Adjusted EPS and EBITDA
are non-GAAP financial measures presented herein, are not
calculated or presented in accordance with GAAP, and should be
considered in addition to, but not as a substitute for, or superior
to, financial measures prepared in accordance with GAAP. These
non-GAAP financial measures are determined by excluding certain
amounts, expenses, income or other impacts, including the impact of
discrete tax items, from the corresponding financial measures
determined in accordance with GAAP.
Due to the inherent difficulty of forecasting the timing and
amount of certain items that would impact EPS and net income,
including discrete tax items, the Company is unable to reasonably
estimate the related impact of such items to EPS and net income,
the GAAP financial measures most directly comparable to adjusted
EPS and EBITDA, respectively. Accordingly, the Company is unable to
provide a reconciliation of either adjusted EPS to EPS or EBITDA to
net income. For the same reasons, the Company is unable to address
the probable significance of the unavailable information, which
could have a significant impact on the Company's full-year 2017
GAAP financial results. In 2017, amortization of intangible assets
is expected to be approximately $1.54
per share.
Safe Harbor Statement
This press release contains forward-looking statements,
including, but not limited to, our 2016 and 2017 guidance and our
statements related to the Company's plans, objectives, expectations
(financial and otherwise) or intentions. Actual results may differ
materially from those projected or suggested in any forward-looking
statements. Factors that may impact these forward-looking
statements can be found in Management's Discussion and Analysis of
Financial Condition and Results of Operations and Item 1A – "Risk
Factors" in the Company's Annual Report on Form 10-K filed with the
SEC on February 16, 2016. A copy of
this document can be found at the Investor Information section of
Express Scripts' web site at
http://www.express-scripts.com/corporate.
We do not undertake any obligation to release publicly any
revisions to such forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
1 Throughout this press release, "earnings per
diluted share" and "EPS" refer to earnings per diluted share
attributable to Express Scripts, excluding non-controlling interest
representing the share allocated to members of our consolidated
affiliates.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/express-scripts-holding-company-announces-2017-financial-guidance-300377688.html
SOURCE Express Scripts Holding Company